Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A McAfee

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors|July 9, 2004
Depressed mood and smoking experimentation among preteensMichael R Polen, Susan J Curry, Louis C Grothaus, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 16, 2004
Return on investment of different combinations of bupropion SR dose and behavioral treatment for smoking cessation in a health care setting: an employer's perspectiveHarold S Javitz, Gary E Swan, Susan M Zbikowski, et al.
Journal of Cardiovascular Pharmacology|January 27, 2011
Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigsJeff Bechard, John Ken Gibson, Cheryl R Killingsworth, et al.
The American Journal of Managed Care|March 23, 2004
Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspectiveHarold S Javitz, Gary E Swan, Susan M Zbikowski, et al.
Journal of General Internal Medicine|February 25, 2009
Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking vareniclineJennifer B McClure, Gary E Swan, Lisa Jack, et al.
Translational Behavioral Medicine|July 7, 2011
Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessationHarold S Javitz, Susan M Zbikowski, Mona Deprey, et al.
Anti-Cancer Drug Design|October 2, 1998
1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activityA B Kelson, J P McNamara, A Pandey, et al.
American Journal of Preventive Medicine|April 23, 2010
Behavioral counseling and varenicline treatment for smoking cessationGary E Swan, Jennifer B McClure, Lisa M Jack, et al.
Journal of Substance Abuse Treatment|November 14, 2008
Impact of symptoms experienced by varenicline users on tobacco treatment in a real world settingAbigail C Halperin, Timothy A McAfee, Lisa M Jack, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|February 19, 2011
Utilization of services in a randomized trial testing phone- and web-based interventions for smoking cessationSusan M Zbikowski, Lisa M Jack, Jennifer B McClure, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors|July 9, 2004
Depressed mood and smoking experimentation among preteensMichael R Polen, Susan J Curry, Louis C Grothaus, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 16, 2004
Return on investment of different combinations of bupropion SR dose and behavioral treatment for smoking cessation in a health care setting: an employer's perspectiveHarold S Javitz, Gary E Swan, Susan M Zbikowski, et al.
Journal of Cardiovascular Pharmacology|January 27, 2011
Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigsJeff Bechard, John Ken Gibson, Cheryl R Killingsworth, et al.
The American Journal of Managed Care|March 23, 2004
Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspectiveHarold S Javitz, Gary E Swan, Susan M Zbikowski, et al.
Journal of General Internal Medicine|February 25, 2009
Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking vareniclineJennifer B McClure, Gary E Swan, Lisa Jack, et al.
Translational Behavioral Medicine|July 7, 2011
Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessationHarold S Javitz, Susan M Zbikowski, Mona Deprey, et al.
Anti-Cancer Drug Design|October 2, 1998
1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activityA B Kelson, J P McNamara, A Pandey, et al.
American Journal of Preventive Medicine|April 23, 2010
Behavioral counseling and varenicline treatment for smoking cessationGary E Swan, Jennifer B McClure, Lisa M Jack, et al.
Journal of Substance Abuse Treatment|November 14, 2008
Impact of symptoms experienced by varenicline users on tobacco treatment in a real world settingAbigail C Halperin, Timothy A McAfee, Lisa M Jack, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|February 19, 2011
Utilization of services in a randomized trial testing phone- and web-based interventions for smoking cessationSusan M Zbikowski, Lisa M Jack, Jennifer B McClure, et al.
Pageof 7